Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to IxazomibSudhir Manda, Robert M. Rifkin, Christopher A. Yasenchak et al.|Clinical Lymphoma Myeloma & Leukemia|2020Cited by 16
PF729 LONG‐TERM PROTEASOME INHIBITION (LTPI) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): US MM‐6, A REAL‐WORLD (RW) STUDY TRANSITIONING FROM BORTEZOMIB (BTZ) TO IXAZOMIB (IXA)Robert M. Rifkin, Ralph V. Boccia, Habte Yimer et al.|HemaSphere|2019Cited by 1